AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

AstraZeneca shares fell 1.7% after an FDA advisory panel voted against recommending its experimental breast cancer treatment. The decision is a negative regulatory signal for the drug candidate and raises uncertainty around approval prospects. The news is likely to pressure the stock, but the broader market impact should be limited.

Analysis

AstraZeneca shares fell 1.7% after an FDA advisory panel voted against recommending its experimental breast cancer treatment. The decision is a negative regulatory signal for the drug candidate and raises uncertainty around approval prospects. The news is likely to pressure the stock, but the broader market impact should be limited.